Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 220

1.

Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.

Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB.

J Intern Med. 2010 Sep;268(3):296-308. doi: 10.1111/j.1365-2796.2010.02252.x. Epub 2010 May 28.

PMID:
20561148
[PubMed - indexed for MEDLINE]
2.

Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.

Persson M, Engström G, Björkbacka H, Hedblad B.

Atherosclerosis. 2012 Feb;220(2):502-5. doi: 10.1016/j.atherosclerosis.2011.10.039. Epub 2011 Nov 9.

PMID:
22119508
[PubMed - indexed for MEDLINE]
3.

Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.

Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N.

J Natl Cancer Inst. 1999 May 19;91(10):869-74.

PMID:
10340907
[PubMed - indexed for MEDLINE]
Free Article
4.

The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men.

Haugaard SB, Andersen O, Hansen TW, Eugen-Olsen J, Linneberg A, Madsbad S, Olsen MH, Jørgensen T, Borch-Johnsen K, Jeppesen J.

Diabet Med. 2012 Apr;29(4):479-87. doi: 10.1111/j.1464-5491.2011.03513.x.

PMID:
22050462
[PubMed - indexed for MEDLINE]
5.

Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.

Lyngbæk S, Marott JL, Sehestedt T, Hansen TW, Olsen MH, Andersen O, Linneberg A, Haugaard SB, Eugen-Olsen J, Hansen PR, Jeppesen J.

Int J Cardiol. 2013 Sep 10;167(6):2904-11. doi: 10.1016/j.ijcard.2012.07.018. Epub 2012 Aug 19.

PMID:
22909410
[PubMed - indexed for MEDLINE]
6.

Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.

Sidenius N, Sier CF, Ullum H, Pedersen BK, Lepri AC, Blasi F, Eugen-Olsen J.

Blood. 2000 Dec 15;96(13):4091-5.

PMID:
11110678
[PubMed - indexed for MEDLINE]
Free Article
7.

Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.

Lomholt AF, Christensen IJ, Høyer-Hansen G, Nielsen HJ.

Acta Oncol. 2010 Aug;49(6):805-11. doi: 10.3109/0284186X.2010.491086.

PMID:
20524776
[PubMed - indexed for MEDLINE]
8.

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.

Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P.

JAMA. 2005 Apr 6;293(13):1609-16.

PMID:
15811980
[PubMed - indexed for MEDLINE]
9.

Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.

Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F.

Liver Int. 2012 Mar;32(3):500-9. doi: 10.1111/j.1478-3231.2011.02665.x. Epub 2011 Oct 17.

PMID:
22098627
[PubMed - indexed for MEDLINE]
10.

The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality.

Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, Eugen-Olsen J.

Clin Microbiol Infect. 2004 May;10(5):409-15.

PMID:
15113317
[PubMed - indexed for MEDLINE]
11.

Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.

Riisbro R, Christensen IJ, Nielsen HJ, Brünner N, Nilbert M, Fernebro E.

Int J Biol Markers. 2005 Apr-Jun;20(2):93-102.

PMID:
16011039
[PubMed - indexed for MEDLINE]
12.
13.

Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.

Pawlak K, Buraczewska-Buczko A, Mysliwiec M, Pawlak D.

Am J Med Sci. 2010 Jan;339(1):5-9. doi: 10.1097/MAJ.0b013e3181b922a4.

PMID:
19926968
[PubMed - indexed for MEDLINE]
14.

High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test.

Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Haaland MB, Aaby P, Eugen-Olsen J.

Trop Med Int Health. 2009 Sep;14(9):986-94. doi: 10.1111/j.1365-3156.2009.02328.x.

PMID:
19725925
[PubMed - indexed for MEDLINE]
Free Article
15.

Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.

Lyngbæk S, Marott JL, Møller DV, Christiansen M, Iversen KK, Clemmensen PM, Eugen-Olsen J, Jeppesen JL, Hansen PR.

Am J Cardiol. 2012 Dec 15;110(12):1756-63. doi: 10.1016/j.amjcard.2012.08.008. Epub 2012 Sep 13.

PMID:
22981263
[PubMed - indexed for MEDLINE]
16.

Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.

Fernebro E, Madsen RR, Fernö M, Brünner N, Bendahl P, Christensen IJ, Johnson A, Nilbert M.

Eur J Cancer. 2001 Mar;37(4):486-91.

PMID:
11267858
[PubMed - indexed for MEDLINE]
17.

Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals.

Langkilde A, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, Jeppesen J, Eugen-Olsen J.

Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):609-18. doi: 10.1158/1055-9965.EPI-10-1009. Epub 2011 Jan 14.

PMID:
21239684
[PubMed - indexed for MEDLINE]
Free Article
18.

Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.

Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B.

Am J Kidney Dis. 2006 Jan;47(1):139-48.

PMID:
16377395
[PubMed - indexed for MEDLINE]
19.

Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.

Olson FJ, Thurison T, Ryndel M, Høyer-Hansen G, Fagerberg B.

Clin Biochem. 2010 Jan;43(1-2):124-30. doi: 10.1016/j.clinbiochem.2009.09.028. Epub 2009 Oct 12.

PMID:
19822140
[PubMed - indexed for MEDLINE]
20.

Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.

Koch A, Voigt S, Kruschinski C, Sanson E, Dückers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F.

Crit Care. 2011;15(1):R63. doi: 10.1186/cc10037. Epub 2011 Feb 16.

PMID:
21324198
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk